Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Esperion Therapeutics, Inc. (ESPR) reported earnings of 34 cents per share in the first quarter of 2024, against the Zacks Consensus Estimate of a loss of 8 cents. The company incurred a loss of 79 cents per share in the year-ago quarter.Esperion generated revenues of $137.7 million, up nearly 467% year over year. The upside was driven by the receipt of a milestone payment and increased demand for the company’s drugs across all regions. Per management, this is the highest level of revenues generated by the ...